Is PharmaCyte Biotech, Inc. (PMCB) Halal?
Shariah Screening — 5 Standards
Based on financial data from April 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 0.0% / 30% | 203.6% / 30% | 48.4% / 30% | N/A | ✗ NOT HALAL |
| DJIM | 0.0% / 33% | 203.6% / 33% | 48.4% / 33% | N/A | ✗ NOT HALAL |
| MSCI | 0.0% / 33% | 28.2% / 33% | 6.7% / 33% | N/A | ✓ HALAL |
| S&P | 0.0% / 33% | 203.6% / 33% | 48.4% / 33% | N/A | ✗ NOT HALAL |
| FTSE | 0.0% / 33% | 28.2% / 33% | 6.7% / 50% | N/A | ✓ HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | 0.0% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -8.2% | |
| Return on Assets (ROA) | -6.8% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$3M |
| Free Cash Flow | -$3M |
| Current Ratio | 12.3 |
| Total Assets | $55M |
Price & Trading
| Last Close | $0.78 |
| 50-Day MA | $0.75 |
| 200-Day MA | $0.90 |
| Avg Volume | 255K |
| Beta | 0.4 |
|
52-Week Range
$0.63
| |
About PharmaCyte Biotech, Inc. (PMCB)
PharmaCyte Biotech, Inc., a biotechnology company, focused on developing and preparing to commercialize cellular therapies for cancer using live cell encapsulation technology in the United States. The company's cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer. It also develops CypCaps for pancreatic cancer and other solid cancerous tumors. It has a cooperation agreement with Iroquois Master Fund Ltd.; license agreements with SG Austria Pte. Ltd.; and Austrianova Singapore Pte. Ltd. to use the Cell-in-the-Box technology for cancer treatment. The company was formerly known as Nuvilex, Inc. and changed its name to PharmaCyte Biotech, Inc. in January 2015. PharmaCyte Biotech, Inc. was incorporated in 1996 and is headquartered in Las Vegas, Nevada.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is PharmaCyte Biotech, Inc. (PMCB) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), PharmaCyte Biotech, Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is PharmaCyte Biotech, Inc.'s debt ratio?
PharmaCyte Biotech, Inc.'s debt ratio is 0.0% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 0.0%.
What are PharmaCyte Biotech, Inc.'s key financial metrics?
PharmaCyte Biotech, Inc. has a market capitalization of $8M. Return on equity stands at -8.2%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.